Literature DB >> 28885639

Targeting Immune Checkpoints in Cancer Therapy.

Suzanne L Topalian1,2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28885639     DOI： 10.1001/jama.2017.14155

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  45 in total

1.  Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Authors:  Marieke F Fransen; Mark Schoonderwoerd; Philipp Knopf; Marcel Gm Camps; Lukas Jac Hawinkels; Manfred Kneilling; Thorbald van Hall; Ferry Ossendorp
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Innate B Cells: the Archetype of Protective Immune Cells.

Authors:  Alexis Grasseau; Marina Boudigou; Laëtitia Le Pottier; Nedra Chriti; Divi Cornec; Jacques-Olivier Pers; Yves Renaudineau; Sophie Hillion
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

3.  Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.

Authors:  Apostolia M Tsimberidou; Laura A Levit; Richard L Schilsky; Steven D Averbuch; Daniel Chen; John M Kirkwood; Lisa M McShane; Elad Sharon; Kathryn F Mileham; Michael A Postow
Journal:  J Clin Oncol       Date:  2018-10-19       Impact factor: 44.544

4.  Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

Authors:  Jeremy M O'Connor; Kristen L Fessele; Jean Steiner; Kathi Seidl-Rathkopf; Kenneth R Carson; Nathan C Nussbaum; Emily S Yin; Kerin B Adelson; Carolyn J Presley; Anne C Chiang; Joseph S Ross; Amy P Abernethy; Cary P Gross
Journal:  JAMA Oncol       Date:  2018-08-09       Impact factor: 31.777

5.  Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma.

Authors:  Aurélie Collignon; Françoise Silvy; Stéphane Robert; Malika Trad; Sébastien Germain; Jérémy Nigri; Frédéric André; Véronique Rigot; Richard Tomasini; Bernard Bonnotte; Dominique Lombardo; Eric Mas; Evelyne Beraud
Journal:  Oncoimmunology       Date:  2018-09-25       Impact factor: 8.110

Review 6.  Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives.

Authors:  Pasquale Persico; Elena Lorenzi; Angelo Dipasquale; Federico Pessina; Pierina Navarria; Letterio S Politi; Armando Santoro; Matteo Simonelli
Journal:  J Clin Med       Date:  2021-03-26       Impact factor: 4.241

Review 7.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

8.  IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.

Authors:  Jianmin Zhu; Jin-Qing Liu; Min Shi; Xinhua Cheng; Miao Ding; Jianchao C Zhang; Jonathan P Davis; Sanjay Varikuti; Abhay R Satoskar; Lanchun Lu; Xueliang Pan; Pan Zheng; Yang Liu; Xue-Feng Bai
Journal:  JCI Insight       Date:  2018-04-05

9.  Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors.

Authors:  Jeremy M O'Connor; Kathi Seidl-Rathkopf; Aracelis Z Torres; Paul You; Kenneth R Carson; Joseph S Ross; Cary P Gross
Journal:  Oncologist       Date:  2018-07-16

10.  Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.

Authors:  Musa AlHarbi; Nahla Ali Mobark; Latifa AlMubarak; Rasha Aljelaify; Mariam AlSaeed; Amal Almutairi; Fatmah Alqubaishi; M Emarat Hussain; Ali Abdullah O Balbaid; Amal Said Marie; Lamia AlSubaie; Saeed AlShieban; Nada alTassan; Shakti H Ramkissoon; Malak Abedalthagafi
Journal:  Oncologist       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.